Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity

Cyclooxygenase-2 (COX-2), a rate-limiting enzyme for prostanoid synthesis, has been implicated in the neurotoxicity resulting from hypoxia-ischemia, and its inhibition has therapeutic potential for ischemic stroke. However, COX-2 inhibitors increase the risk of cardiovascular complications. We therefore sought to identify the downstream effectors of COX-2 neurotoxicity, and found that prostaglandin E2 EP1 receptors are essential for the neurotoxicity mediated by COX-2–derived prostaglandin E2. EP1 receptors disrupt Ca2+ homeostasis by impairing Na+-Ca2+ exchange, a key mechanism by which neurons cope with excess Ca2+ accumulation after an excitotoxic insult. Thus, EP1 receptors contribute to neurotoxicity by augmenting the Ca2+ dysregulation underlying excitotoxic neuronal death. Pharmacological inhibition or gene inactivation of EP1 receptors ameliorates brain injury induced by excitotoxicity, oxygen glucose deprivation and middle cerebral artery (MCA) occlusion. An EP1 receptor inhibitor reduces brain injury when administered 6 hours after MCA occlusion, suggesting that EP1 receptor inhibition may be a viable therapeutic option in ischemic stroke.

[1]  L. Audoly,et al.  Identification of specific EP receptors responsible for the hemodynamic effects of PGE2. , 1999, American journal of physiology. Heart and circulatory physiology.

[2]  N. Rothwell,et al.  Cleavage of the Plasma Membrane Na+/Ca2+ Exchanger in Excitotoxicity , 2005, Cell.

[3]  A. Lee,et al.  Aminoacetyl moiety as a potential surrogate for diacylhydrazine group of SC-51089, a potent PGE2 antagonist, and its analogs. , 1996, Journal of medicinal chemistry.

[4]  V. Pinelis,et al.  On the origin of a sustained increase in cytosolic Ca2+ concentration after a toxic glutamate treatment of the nerve cell culture , 1993, FEBS letters.

[5]  K. Nakao,et al.  Role of Prostaglandin E Receptor EP1 Subtype in the Development of Renal Injury in Genetically Hypertensive Rats , 2003, Hypertension.

[6]  Garret A. FitzGerald,et al.  COX-2 and beyond: approaches to prostaglandin inhibition in human disease , 2003, Nature Reviews Drug Discovery.

[7]  Charles Tator,et al.  Secondary Ca2+ overload indicates early neuronal injury which precedes staining with viability indicators , 1993, Brain Research.

[8]  R. P. Kraig,et al.  Prostaglandin E Receptor Subtypes in Cultured Rat Microglia and Their Role in Reducing Lipopolysaccharide‐Induced Interleukin‐1 β Production , 1999, Journal of neurochemistry.

[9]  Eric J Topol,et al.  Failing the public health--rofecoxib, Merck, and the FDA. , 2004, The New England journal of medicine.

[10]  M. Wirenfeldt,et al.  Microglial cell population dynamics in the injured adult central nervous system , 2005, Brain Research Reviews.

[11]  M. Ross,et al.  Cyclooxygenase-2 Contributes to Functional Hyperemia in Whisker-Barrel Cortex , 2000, The Journal of Neuroscience.

[12]  M. Ross,et al.  Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  G. Pignataro,et al.  Pharmacology of Brain Na+/Ca2+ Exchanger: From Molecular Biology to Therapeutic Perspectives , 2004, Pharmacological Reviews.

[14]  C. Iadecola,et al.  The Class B Scavenger Receptor CD36 Mediates Free Radical Production and Tissue Injury in Cerebral Ischemia , 2005, The Journal of Neuroscience.

[15]  N. Bazan,et al.  Lipid signaling: sleep, synaptic plasticity, and neuroprotection. , 2005, Prostaglandins & other lipid mediators.

[16]  L. Minghetti.  Cyclooxygenase‐2 (COX‐2) in Inflammatory and Degenerative Brain Diseases , 2004, Journal of neuropathology and experimental neurology.

[17]  R. Botting,et al.  Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition , 2004, Pharmacological Reviews.

[18]  L. McCullough,et al.  Neuroprotective Function of the PGE2 EP2 Receptor in Cerebral Ischemia , 2004, The Journal of Neuroscience.

[19]  N. Carlson.  Neuroprotection of cultured cortical neurons mediated by the cyclooxygenase‐2 inhibitor APHS can be reversed by a prostanoid , 2003, Journal of neuroscience research.

[20]  G. FitzGerald,et al.  Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. , 1993, The Journal of biological chemistry.

[21]  R. Breyer,et al.  Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. , 2004, Pharmacology & therapeutics.

[22]  L. Kiedrowski.  N-methyl-D-aspartate Excitotoxicity : Relationships among Plasma Membrane Potential , Na 1 / Ca 2 1 Exchange , Mitochondrial Ca 2 1 Overload , and Cytoplasmic Concentrations of Ca 2 1 , H 1 , and K 1 , 1999 .

[23]  Samuel Thayer,et al.  Glutamate-induced calcium transient triggers delayed calcium overload and neurotoxicity in rat hippocampal neurons , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[24]  S. Doré,et al.  Prostaglandin EP4 receptor agonist protects against acute neurotoxicity , 2005, Brain Research.

[25]  D. Choi.  Neurodegeneration: Cellular defences destroyed , 2005, Nature.

[26]  M. Ross,et al.  Cyclo-Oxygenase-2 Gene Expression in Neurons Contributes to Ischemic Brain Damage , 1997, The Journal of Neuroscience.

[27]  M. Ross,et al.  Prostanoids, not reactive oxygen species, mediate COX‐2–dependent neurotoxicity , 2004, Annals of neurology.

[28]  B. Khodorov.  Glutamate-induced deregulation of calcium homeostasis and mitochondrial dysfunction in mammalian central neurones. , 2004, Progress in biophysics and molecular biology.

[29]  Q. Wang,et al.  PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis , 2004, Annals of neurology.

[30]  M. Tymianski,et al.  Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death , 2007, Molecular Neurobiology.